State Ledger
Company profile

MBX Biosciences, Inc. CIK 1776111

Ticker
MBX (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Carmel, IN 46032
Fiscal year end
2025 (FY)
Market Data
Close
$53.24
Change
-$0.02
Change %
-0.03%
Volume
35,408

MBX · trading date Oct 9, 2026 · previous close $53.26 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$86.97M
Total assets
$385.14M
Total liabilities
$15.92M
Stockholders' equity
$369.22M
Cash & equivalents
$75.29M
Operating income
-$98.06M
Operating cash flow
-$79.95M
Capital expenditures
$1.93M

Fiscal year 2025, via 10-K filed 2026-03-12. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$81.88M
Free cash flow margin
—
Liabilities / assets
4.1%
Equity / assets
95.9%
CapEx / revenue
—
Operating cash flow / net income
0.92×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$86.97M $385.14M $15.92M $369.22M
2024 — -$61.92M $268.54M $11.09M $257.44M
2023 — -$32.56M $84.18M $4.29M -$72.47M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-08-27
Financials filed via
Form 10-K
filed 2026-03-12

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Carmel, IN 46032
11711 N. MERIDIAN STREET
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:31 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Indiana — Public Companies